HLA-B

Across TCGA pan-cancer cohorts, HLA-B mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated HLA-B data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HLA-B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HLA-B expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where HLA-B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.622	0.802	.009	11	view →
GBM	DFS	Tertile	All	0.263	0.509	.026	4	view →
LSCC	DFS	Tertile	II,III,IV	0.533	0.835	.034	3	view →
HNSC	DFS	Quartile	II,III,IV	0.855	0.978	.033	3	view →
LUAD	DFS	Quartile	III,IV	0.930	0.433	.017	3	view →
UCEC	DFS	Quartile	All	0.966	0.805	.033	2	view →
CCRCC	DFS	Tertile	All	0.879	0.581	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

HLA-B–PDAC (DFS)

Open the PDAC breakdown →